95 related articles for article (PubMed ID: 29044505)
1. Diagnostic pathology of early systemic cancer: ERBB2 gene amplification in single disseminated cancer cells determines patient survival in operable esophageal cancer.
Hoffmann M; Pasch S; Schamberger T; Maneck M; Möhlendick B; Schumacher S; Brockhoff G; Knoefel WT; Izbicki J; Polzer B; Stoecklein NH; Klein CA
Int J Cancer; 2018 Feb; 142(4):833-843. PubMed ID: 29044505
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE
Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596
[TBL] [Abstract][Full Text] [Related]
4. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
Mrhalová M; Kodet R; Kalinová M; Hilská I
Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
[TBL] [Abstract][Full Text] [Related]
5. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
Kallioniemi OP; Kallioniemi A; Kurisu W; Thor A; Chen LC; Smith HS; Waldman FM; Pinkel D; Gray JW
Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5321-5. PubMed ID: 1351679
[TBL] [Abstract][Full Text] [Related]
6. Targeted transcript quantification in single disseminated cancer cells after whole transcriptome amplification.
Durst FC; Grujovic A; Ganser I; Hoffmann M; Ugocsai P; Klein CA; Czyż ZT
PLoS One; 2019; 14(8):e0216442. PubMed ID: 31430289
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations in ERBB2-amplified breast carcinomas.
Isola J; Chu L; DeVries S; Matsumura K; Chew K; Ljung BM; Waldman FM
Clin Cancer Res; 1999 Dec; 5(12):4140-5. PubMed ID: 10632352
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
[TBL] [Abstract][Full Text] [Related]
9. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
10. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma.
Walch A; Specht K; Braselmann H; Stein H; Siewert JR; Hopt U; Höfler H; Werner M
Int J Cancer; 2004 Dec; 112(5):747-53. PubMed ID: 15386389
[TBL] [Abstract][Full Text] [Related]
11. Determination of True ERBB2 Gene Amplification in Breast Cancer by Quantitative PCR Using a Reference and a Novel Control Gene.
Chamizo C; Rojo F; Madoz-Gúrpide J
Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):179-87. PubMed ID: 25789534
[TBL] [Abstract][Full Text] [Related]
12. Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer.
Tafe LJ; Steinmetz HB; Allen SF; Dokus BJ; Tsongalis GJ
J Clin Pathol; 2015 Apr; 68(4):306-8. PubMed ID: 25576545
[TBL] [Abstract][Full Text] [Related]
13. ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas.
Arrington AK; Dahlberg PS; Davydova J; Vickers SM; Yamamoto M
Surgery; 2009 Aug; 146(2):213-9. PubMed ID: 19628076
[TBL] [Abstract][Full Text] [Related]
14. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
Mrhalova M; Kodet R
J Cancer Res Clin Oncol; 2007 May; 133(5):321-9. PubMed ID: 17165026
[TBL] [Abstract][Full Text] [Related]
15. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
[TBL] [Abstract][Full Text] [Related]
16. [DNA structural features on the borders of ERBB2 amplicons in breast cancer].
Matsenko NIu; Kovalenko SP
Mol Biol (Mosk); 2013; 47(5):818-27. PubMed ID: 25509354
[TBL] [Abstract][Full Text] [Related]
17. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.
Janbabai G; Oladi Z; Farazmandfar T; Taghvaei T; Naghshvar F
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1945-52. PubMed ID: 25820598
[TBL] [Abstract][Full Text] [Related]
19. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
Savinainen KJ; Saramäki OR; Linja MJ; Bratt O; Tammela TL; Isola JJ; Visakorpi T
Am J Pathol; 2002 Jan; 160(1):339-45. PubMed ID: 11786427
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
